Business Context and Reporting Period
Company: Organogenesis Holdings Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 7, 2019
Reporting Period: The filing addresses events occurring on March 7, 2019, regarding the delisting of the Company's warrants from the Nasdaq Stock Market.
Key Financial Metrics
This filing is a current report regarding a corporate governance and listing event. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
- Warrant Delisting: Nasdaq notified the Company on March 7, 2019, of its plan to file a Form 25 with the SEC to formally delist the Company's warrants.
- Reason for Delisting: The delisting is due to non-compliance with the minimum 400 round lot holder requirement for initial listing under Nasdaq Listing Rule 5515(a)(4), as previously disclosed in a January 7, 2019, filing.
- Effective Date: The delisting will become effective ten days after Nasdaq files the Form 25 with the SEC.
- Future Trading Venue: Trading of the warrants is expected to continue on the OTC market under the symbol "ORGOW."
Guidance, Outlook, and Risks
Outlook: The Company anticipates that warrant trading will transition to the OTC market. No specific financial guidance or operational outlook is provided in this report.
Risks and Contingencies: The filing includes forward-looking statements regarding the future trading of warrants on the OTC market. Key risks identified include:
- The Company's ability to meet applicable OTC market requirements.
- Other risks and uncertainties described in other SEC filings.
Unusual Items: The filing notes that the Company undertakes no commitment to update or revise forward-looking statements except as required by applicable securities laws.
Investor Verification Checklist
- Verify the filing date of the Form 25 by Nasdaq to determine the exact effective date of the delisting.
- Confirm the ticker symbol "ORGOW" for the warrants on the OTC market.
- Review the January 7, 2019, Form 8-K for the initial disclosure regarding the failure to meet the 400 round lot holder requirement.
- Check subsequent filings to ensure the Company meets OTC market listing requirements.